Lee Pitcher Portrait

Lee Pitcher

Labour - Doncaster East and the Isle of Axholme

2,311 (5.9%) majority - 2024 General Election

First elected: 4th July 2024



Division Voting information

During the current Parliament, Lee Pitcher has voted in 566 divisions, and never against the majority of their Party.
View All Lee Pitcher Division Votes

Debates during the 2024 Parliament

Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.

Sparring Partners
Lucy Powell (Labour (Co-op))
Secretary of State for Education
(39 debate interactions)
Alan Campbell (Labour)
Lord President of the Council and Leader of the House of Commons
(20 debate interactions)
Sally Jameson (Labour (Co-op))
Parliamentary Secretary and Parliamentary Under-Secretary of State (Cabinet Office) (Jointly with the Ministry for Housing, Communities and Local Government)
(11 debate interactions)
View All Sparring Partners
Department Debates
Department for Transport
(33 debate contributions)
Leader of the House
(31 debate contributions)
Department of Health and Social Care
(23 debate contributions)
View All Department Debates
View all Lee Pitcher's debates

Doncaster East and the Isle of Axholme Petitions

e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.

If an e-petition reaches 10,000 signatures the Government will issue a written response.

If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).

Petition Debates Contributed

Create a public register of all offenders convicted of animal abuse and introduce an automatic, lifetime ban on animal ownership for anyone convicted of animal neglect or abuse. This register should be searchable by vets, breeders, charities and the public to prevent repeat offending.

Lower the age for when you are first called to 40 and provide funding to carry out Mammograms Annually instead of every Three Years

Many tests on dogs and other animals cause unimaginable suffering. They can translate poorly into effective treatments and cures for human diseases or provide safety and efficacy data that is not relevant to humans.

Fund mandatory offer of testing for Type 1 Diabetes in babies, toddlers, and young children as a routine part of medical assessments at the point of care.

We urge the UK Government to scrap plans to extend ILR from 5 to 10 years. We feel that legal migrants, especially care workers, followed the rules and built lives here under the 5-year promise. We think they support vital services and deserve fairness, not shifting rules.

The Government should keep the current 5-year route to Indefinite Leave to Remain (ILR) and restrict access to government benefits for new ILR holders.

Ban the sale of fireworks to the general public to minimise the harm caused to vulnerable people and animals. Defenceless animals can die from the distress caused by fireworks.

I believe that permitting unregulated use of fireworks is an act of wide-scale cruelty to animals.

We think each year, individuals suffer because of loud fireworks. We believe horses, dogs, cats, livestock and wildlife can be terrified by noisy fireworks and many people find them intolerable.


Latest EDMs signed by Lee Pitcher

2nd July 2026
Lee Pitcher signed this EDM on Thursday 9th July 2026

Key Stage 2 Sats Results and the Pearson-Administered National Curriculum Assessment

Tabled by: Shockat Adam (Independent - Leicester South)
That this House notes with concern that Key Stage 2 Sats results have been delayed until 16 July 2026, over a week after the scheduled date of 7 July; further notes that this is the first year of Pearson's £180 million contract to administer the tests, following its takeover from …
11 signatures
(Most recent: 13 Jul 2026)
Signatures by party:
Labour: 4
Green Party: 4
Independent: 2
Democratic Unionist Party: 1
1st July 2026
Lee Pitcher signed this EDM on Thursday 9th July 2026

Carbon monoxide alarms

Tabled by: Gill Furniss (Labour - Sheffield Brightside and Hillsborough)
That this House mourns the tragic death of Cherish Bean; recognises the work that her mother Devon Andrews has done since her passing to raise awareness of the dangers of carbon monoxide; commends her for garnering more than 20,000 signatures on her petition; notes research from the UK Health Security …
21 signatures
(Most recent: 16 Jul 2026)
Signatures by party:
Labour: 14
Liberal Democrat: 3
Democratic Unionist Party: 1
Conservative: 1
Reform UK: 1
Independent: 1
View All Lee Pitcher's signed Early Day Motions

Commons initiatives

These initiatives were driven by Lee Pitcher, and are more likely to reflect personal policy preferences.

MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.


Lee Pitcher has not been granted any Urgent Questions

1 Adjournment Debate led by Lee Pitcher

Tuesday 25th February 2025

1 Bill introduced by Lee Pitcher


A Bill to make provision about the installation and maintenance of, and access to, safety equipment at reservoirs; to create an offence of damaging or destroying safety equipment near bodies of water; to make provision about the teaching of water safety in schools; and for connected purposes.

Commons - 20%

Last Event - 1st Reading
Wednesday 5th February 2025
(Read Debate)

Latest 50 Written Questions

(View all written questions)
Written Questions can be tabled by MPs and Lords to request specific information information on the work, policy and activities of a Government Department
1st Jun 2026
To ask the Minister for the Cabinet Office, how many deaths related to open water swimming have been recorded in England in 2026 to date.

The information requested falls under the remit of the UK Statistics Authority.

A response to the Hon gentleman’s Parliamentary Question of 1st June is attached.

Satvir Kaur
Parliamentary Under-Secretary (Home Office)
18th Jun 2026
To ask the Secretary of State for Business and Trade, if he will make it his policy to designate Monday 20 July 2026 as an additional bank holiday in the event of England winning the 2026 FIFA World Cup final on Sunday 19 July 2026.

The government will be backing the Scotland and England teams all the way as they seek glory at the FIFA World Cup.

The current pattern of bank holidays is well established. While an additional bank holiday may benefit some communities and sectors, the cost to the economy is considerable. The latest analysis estimates the cost to the UK economy for a one-off bank holiday to be around £2 billion.

Kate Dearden
Minister of State (Department for Business, Innovation, Science and Trade)
8th Jul 2026
To ask the Secretary of State for Energy Security and Net Zero, what steps his Department is taking to ensure continuous support for landfill gas generation and methane abatement assets immediately following the end of the Renewables Obligation in April 2027 and while his Department is exploring implementation of a long-term methane capture scheme.

I refer the hon. Member to the answer I gave to my hon Friend the Member for South Derbyshire (Samantha Niblett) on 2nd July 2026 to Question 14090.

As set out in the Carbon Budget and Growth Delivery Plan, the government is exploring the possibility of a long-term methane capture scheme alongside suitable transitional arrangements. DESNZ will shortly consult on proposals for a possible transitional scheme, including an anticipated delivery timetable.

Michael Shanks
Minister of State (Department for Energy Security and Net Zero)
13th May 2026
To ask the Secretary of State for Energy Security and Net Zero, what financial support his Department has provided to small businesses in the context of recent trends in the level of kerosene costs.

The government recognises that many businesses across the country will see the global events and be concerned about the impact on their fuel bills. We are monitoring the situation closely and actively engaging with industry and trade associations to understand what support may be needed.

My Rt hon Friend the Secretary of State has written to the heating oil industry setting out our expectations that they adhere to the industry’s Code of Practice.

We have also requested the CMA undertake a detailed examination of the heating oil market and we will work closely with the CMA to understand their findings and develop options to increase consumer protection.

Martin McCluskey
Parliamentary Under-Secretary of State (Department for Energy Security and Net Zero)
1st Dec 2025
To ask the Secretary of State for Science, Innovation and Technology, whether her Department plans to review the legal and regulatory framework governing the domestic use of CCTV, with particular reference to protections for individuals whose homes or private spaces are captured by neighbouring security cameras.

The department has no plans to review the current legal and regulatory framework governing the domestic use of CCTV, which can play a useful role in making householders feel safe and helping the police to prevent crime.

Individuals that use CCTV to film outside their property boundary have to comply with the UK’s data protection laws. This means that any personal data captured, such as images, recordings and footage of identifiable individuals, should be processed fairly, lawfully, transparently, and securely.

The Information Commissioner’s Office (ICO), the UK’s independent regulator for data protection, has published practical guidance to help people concerned about intrusive use of CCTV: Home CCTV systems | ICO. Regardless of whether or not the use of CCTV falls within the data protection legislation, the ICO recommends that people use it responsibly to protect the privacy of others.

Where the use of a domestic camera system constitutes harassment or stalking, other, criminal laws will apply.

Ian Murray
Minister of State (Department for Digital, Culture, Media and Sport)
10th Nov 2025
To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to ensure the Online Safety Act 2023 does not result in unintended consequences for (a) freedom of expression and (b) access to (i) supportive and (ii) archival online content.

Under the Act, both Ofcom and in-scope companies will have duties relating to freedom of expression, for which they can be held to account. Platforms will not be able to arbitrarily remove content and users will have access to effective complaints procedures to appeal instances when content is unduly taken down. This will ensure that UK users can express themselves freely online and participate in pluralistic and robust debate.

Kanishka Narayan
Minister of State (Cabinet Office) (Jointly with the Department for Business, Innovation, Science and Technology)
10th Oct 2025
To ask the Secretary of State for Science, Innovation and Technology, what steps her Department is taking to ensure that (a) remote and (b) other hard-to-reach properties are provided access to reliable fibre broadband.

Project Gigabit is the Government’s programme to deliver gigabit-capable broadband to UK premises that are not included in suppliers' commercial plans. Our goal is for nationwide gigabit coverage by 2032, ensuring at least 99% of UK premises can access a gigabit-capable connection.

More than £2.4 billion of Project Gigabit contracts have already been signed to connect over one million more premises with gigabit-capable broadband. These premises fall predominantly in rural areas.

However, our expectation is that some remote premises will remain too expensive to build a gigabit connection to. We continue to consider what can be done to further enable alternatives to fibre connections.

Kanishka Narayan
Minister of State (Cabinet Office) (Jointly with the Department for Business, Innovation, Science and Technology)
16th Jun 2026
To ask the Secretary of State for Culture, Media and Sport, what discussions the Department has had with (a) the Medicines and Healthcare products Regulatory Agency and (b) the Gambling Commission on (i) the responsibilities of gambling operators to warn customers about medication-induced impulse control disorders, including from dopamine agonists, and (ii) whether operators should (A) ask about use of high-risk medications and (B) provide tailored safer gambling tools for those at higher risk.

The Department has not engaged with the Medicines and Healthcare products Regulatory Agency or the Gambling Commission regarding this matter. However, DCMS officials worked with the Gambling Commission to develop their Customer Interaction guidance and vulnerability statement, which sets out how operators should support vulnerable customers, including those who are taking medication which may increase risk-taking.

Ian Murray
Minister of State (Department for Digital, Culture, Media and Sport)
6th Mar 2026
To ask the Secretary of State for Culture, Media and Sport, whether her Department has made an assessment of the ability of places of worship to reclaim VAT on repairs and maintenance works following the replacement of the Listed Places of Worship Grant Scheme with the Places of Worship Renewal Fund.

The Department has not made an assessment of the ability of places of worship to reclaim VAT following the ending of the Listed Places of Worship Grant Scheme.

The Places of Worship Renewal Fund will have a budget of £23 million per year. The Places of Worship Renewal Fund will award grants for projects to cover capital works, rather than just the VAT element of a project, as is the case with the Listed Places of Worship Grant Scheme. In some cases the amount granted could be greater than just the VAT element currently funded.

Ian Murray
Minister of State (Department for Digital, Culture, Media and Sport)
8th Jan 2026
To ask the Secretary of State for Culture, Media and Sport, whether she has made an assessment of the potential impact of ending the Listed Places of Worship Grant Scheme on (a) listed religious buildings and (b) their congregations.

While we have confirmed the extension of the Listed Places of Worship Grant Scheme until 31 March 2026, the future funding of the scheme after this date is being assessed and considered as we work through the output of the Spending Review and the Departmental business planning process.

Ian Murray
Minister of State (Department for Digital, Culture, Media and Sport)
10th Jul 2026
To ask the Secretary of State for Education, what assessment she has made of the adequacy and affordability of childcare provision during school holidays; and what steps her Department is taking to ensure that childcare costs do not prevent parents, particularly women, from remaining in employment.

Improving the cost and availability of childcare is a priority for this government. Families can receive support with costs through Tax-Free Childcare, Universal Credit Childcare and the Flexible Support Fund.

The government has committed over £600 million to the holiday activities and food (HAF) programme from 2026/27, providing children and young people from disadvantaged backgrounds with free meals and enriching activities during school holidays. In a recent survey of 20,000 parents and carers, more that 90% said HAF helped them worry less about money during the holidays and made it easier for them to work.

The department has not assessed the cost of holiday childcare. This year, we are providing £12.9 million to support local authorities with school-age childcare. To monitor this, we are collecting termly data to provide us with a broad picture of the availability of holiday childcare.

Paul Waugh
Parliamentary Under-Secretary (Department for Education)
1st Jun 2026
To ask the Secretary of State for Education, what steps she is taking to ensure that schoolchildren receive adequate water safety education before the summer holiday period.

The PE national curriculum makes specific reference to swimming and water safety, stating that all primary pupils must learn to swim competently and confidently over a distance of at least 25 metres, use a range of strokes effectively and perform safe self-rescue in different water-based situations.

The department has made changes to the statutory relationships, sex and health education guidance for schools to ensure all pupils are taught about the water safety code, supporting them to be safe in different types of water.

Georgia Gould
Minister of State (Education)
12th Jan 2026
To ask the Secretary of State for Environment, Food and Rural Affairs, whether her Department has made an assessment of the potential impact of food imports produced to lower animal welfare standards on the competitiveness of UK farmers.

The Government shares the public’s high regard for the high animal welfare standards we have in this country; they are one of the selling points of our British farming industry and are greatly valued by consumers both at home and abroad.

As set out in the UK’s Trade Strategy, the department will not lower food standards and will uphold high animal welfare standards. Defra recognises concerns about methods of production, such as sow stalls and battery cages, which are not permitted in the UK. While production methods vary in line with different climates, diseases and other contextual reasons, we will always consider whether overseas produce has an unfair advantage and any impact that may have. Where necessary, the Government will be prepared to use the full range of powers at our disposal to protect our most sensitive sectors.

Angela Eagle
Secretary of State for Environment, Food and Rural Affairs
15th May 2025
To ask the Secretary of State for Environment, Food and Rural Affairs, what steps he is taking to promote water reuse.

The Government recognises that recycled water e.g. from rainwater or domestic greywater showers play a key role in helping non-household users and businesses meet the statutory water demand reduction target of 20% by March 2038. We encourage water companies and developers to move from potable water to recycled sources where possible.

To enable reuse in households, we are working to support the water sector to supply treated, non-potable water, including rainwater, for certain water demands such as toilet flushing. To support this, Ofwat consulted on environmental incentives for developers which considered where recycled water could be integrated into buildings and developments, and acknowledged the importance of recycled water to reducing pressure on the water system

Emma Hardy
Minister of State (Department for Environment, Food and Rural Affairs)
3rd Jul 2026
To ask the Secretary of State for Transport, pursuant to the Answer of 17 April 2026 to Question 123626 on Aviation: Crew, if she will provide the number of commercial airline pilots registered with the Civil Aviation Authority who (a) reached the mandatory retirement age of 65 in each of the past five calendar years and (b) will reach the mandatory retirement age of 65 in each of the next 10 calendar years.

The data below accounts for all relevant commercial licence types and relates to pilots who reached the age of 65 during the relevant report year and held a valid commercial licence and valid medical certificate as of 1 January of that year.

Date

Number of Pilots aged 65

1st January 2022

43

1st January 2023

51

1st January 2024

54

1st January 2025

61

1st January 2026

72

The number of pilots that will reach the mandatory age of 65 in the next 10 calendar years can be found on the Civil Aviation Authority’s published data on pilot licence holders by age and sex, which can be found here: https://www.caa.co.uk/data-and-analysis/approved-persons-and-organisations/personnel-licensing-statistics/pilot-licence-holders-by-age-and-sex/ . The data for 2025 will be published in the next few months.

Keir Mather
Parliamentary Under-Secretary (Department for Transport)
3rd Jul 2026
To ask the Secretary of State for Transport, how many commercial airline pilots joined the Civil Aviation Authority register in each of the past five calendar years.

The table below shows the number of pilots that received their first UK commercial pilot licence from the Civil Aviation Authority by year of issue and includes all relevant commercial licence types.

Year of Issue

Initial issues (Commercial Pilots)

2021

625

2022

1374

2023

1771

2024

796

2025

961

Keir Mather
Parliamentary Under-Secretary (Department for Transport)
16th Jun 2026
To ask the Secretary of State for Transport, what information her Department holds on road traffic collisions in which the at-fault driver was taking a dopamine agonist, and on those incidents where (a) speed, (b) loss of control and (c) impulsive risk-taking were recorded as contributory factors.

This information is not held.

Data on deaths and injuries in reported road collisions is based on information reported to the Department by police forces in Great Britain via the system known as STATS19.

STATS19 does not collect information about whether a driver involved in a road casualty collision has been prescribed or taken a dopamine agonist. Additionally, STATS19 does not assign blame to any of the participants in road casualty collisions, so it is not possible to provide the number of collisions where the at-fault driver was taking any drug.

The Department does receive coroner and procurator fiscals’ reports for some deceased drivers involved in road collisions. A feasibility study has been published using this data and STATS19 data to provide some insight into what type and levels of drugs are detected in deceased drivers. This is published at:

https://www.gov.uk/government/statistics/developing-drug-driving-statistics.

Data concerning contributory factors and road safety factors which provide some insight into why and how road collisions occur are published at:

https://www.gov.uk/government/statistical-data-sets/road-safety-statistics-data-tables#road-safety-factors.

Lilian Greenwood
Parliamentary Under-Secretary (Department for Work and Pensions)
20th May 2026
To ask the Secretary of State for Transport, what steps she is taking to increase the speed at which the Driver and Vehicle Licensing Agency processes driving licence renewals.

The quickest way to transact with the Driver and Vehicle Licensing Agency (DVLA) is by using its online services. The DVLA’s target is to dispatch 95 per cent of straightforward online driving licence applications within three working days and 90 per cent of paper applications within ten working days.

The DVLA’s target for driving licence applications where a medical condition must be investigated is to make a decision on average within 50 working days. In the interests of road safety, the DVLA must be satisfied that the required medical standards are met before a licence is issued.

The DVLA has seen an increase in both the volume and complexity of medical driving licence applications, which has increased waiting times for some people. To improve its services, the DVLA has introduced a new casework system, and a new medical services portal, so more people can now apply online through the DVLA’s driver and vehicles account.

These enhancements alongside the recruitment of additional staff to deal with these applications and answer telephone calls are delivering real improvements in services and turnaround times for customers.

Simon Lightwood
Parliamentary Under-Secretary (Department for Transport)
10th Nov 2025
To ask the Secretary of State for Transport, whether her Department has made an assessment of the adequacy of restoration of rail service levels to pre COVID-19 levels.

We regularly review and publish passenger demand levels and work closely with operators to ensure they provide sufficient capacity to meet demand wherever possible. We have been clear with operators that they should meet demand in a manner that supports overall performance improvement and minimises the net subsidy taxpayers pay for rail.

Keir Mather
Parliamentary Under-Secretary (Department for Transport)
10th Nov 2025
To ask the Secretary of State for Transport, whether her Department has made an assessment of the potential impact of bus franchising on community connectivity in rural villages.

The Government is committed to delivering better bus services, including in rural areas. We have set out a plan to achieve this based on giving local leaders the powers they need and empowering them to choose the service model that works best in their area, whether that be franchising, strengthened Enhanced Partnerships, or local authority bus companies.

Under franchised bus services, local authorities can assume responsibility for all elements of the bus network, including routes, timetables and fares. This can lead to improved levels of connectivity. There is no ‘one size fits all’ approach to franchising, and Government is engaging with Local Transport Authorities to identify potential alternative models of franchising that could be adopted and used by smaller or more rural authorities.

The Government has also allocated funding to five different areas to take forward bus franchising pilots. The pilots will test different franchising models to investigate how they can be implemented and deliver improved bus services for passengers, including in more rural locations. The pilots will provide funding, guidance, and practical resources to local transport authorities to identify the most suitable approach to bus franchising and wider bus reform measures.

Simon Lightwood
Parliamentary Under-Secretary (Department for Transport)
10th Oct 2025
To ask the Secretary of State for Transport, with reference to her Department's press release entitled Transport Secretary acts to make thousands of extra driving tests available each month, published on 23 April 2025, how many driving test places have been available to book in each the last six months for which data is available.

The table below shows the number of car practical driving tests provided for the months April 2025 to September 2025.

April

May

June

July

August

September

Total

155,582

161,039

172,327

185,901

158,511

183,762

Simon Lightwood
Parliamentary Under-Secretary (Department for Transport)
6th Jan 2026
To ask the Secretary of State for Work and Pensions, what assessment his Department has made of the potential impact of statutory maternity pay levels on (a) workforce retention and (b) maternal health outcomes.

The Government has committed to review the parental leave and pay system.

Andrew Western
Minister of State (Department for Work and Pensions)
18th Nov 2025
To ask the Secretary of State for Work and Pensions, when the Disability Confident Scheme was last evaluated, what metrics were used, and whether the Department plans to review employer compliance with the guaranteed interview commitment.

In 2022, the department ran a survey to understand from members’ perspectives the impact that signing up to the Disability Confident scheme has had on their organisations. Metrics in the survey included members’ recruitment and retention attitudes and practices towards disabled people, awareness of the benefits of Disability Confident membership, plans for membership renewal, and perceived impact of Disability Confident on the organisation. The findings of the survey can be accessed from: Disability Confident: survey of participating employers, May 2022 - GOV.UK.

DWP is working with stakeholders, including disabled people, the Devolved Governments, local authorities, disability organisations, employers and sector experts to strengthen the scheme. This includes reviewing the current offer of an interview commitment and exploring how we can work with employers to improve transparency and accountability against scheme criteria.

Stephen Timms
Minister of State (Ministry of Housing Communities and Local Government) (Equalities)
21st Oct 2025
To ask the Secretary of State for Work and Pensions, what steps he is taking to improve the Child Maintenance Service.

The Government has announced ambitious plans to reform the CMS.

Moving all cases to a single service, where payments are collected and transferred will provide an improved service, quickly identifying and tackling missed payments and lifting more children out of poverty.


The Government has also been undertaking a review of the child maintenance calculation and announced its intention to publish a consultation.


The Department continues to optimise digital channels, delivering services more efficiently and effectively.

Andrew Western
Minister of State (Department for Work and Pensions)
1st Jul 2026
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve outcomes for people living with migraine.

The Government recognises the significant impact that migraine can have on individuals’ quality of life and is committed to improving care and outcomes for people living with this condition.

NHS England is supporting improvements in migraine care through national programmes such as the RightCare headache and migraine toolkit and the Getting It Right First Time neurology programme. These initiatives support earlier diagnosis, more effective management in primary care, and better access to specialist services where needed, helping to reduce unwarranted variation in care and improve patient outcomes.

To support consistent, high-quality care, the National Institute for Health and Care Excellence (NICE) has published clear, evidence-based guidance on the diagnosis and management of headaches, including migraine. This guidance helps clinicians to diagnose migraine more promptly and provide appropriate acute and preventive treatments based on individual clinical need.

In August 2025, NHS England updated its service specification for specialised adult neurology services. It outlines a number of minimum service requirements for key specialties, including complex headache services.

Over the last five years, a new class of drugs, calcitonin gene-related peptide (CGRP) inhibitors, has been made available on the National Health Service for the prevention and treatment of episodic and chronic migraines. Atogepant is the latest CGRP inhibitor to be recommended by NICE for use as a prevention and acute treatment of migraine.

1st Jul 2026
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the Secretary of State for Health and Social Care on cross-government support for people whose ability to work is affected by migraine.

The Government is committed to working collaboratively to support disabled people and people with health conditions, including people affected by migraine. The Department of Health and Social Care and the Department for Work and Pensions’ Joint Work and Health Directorate was established to co-ordinate Government activity to help disabled people and people with health conditions get good work, get on in that work, and to return to work as quickly as possible if they leave it.

The Department of Health and Social Care and the Department for Work and Pensions have a range of specialist initiatives, including those joining up health and employment support around the individual through programmes such as Employment Advisors in NHS Talking Therapies and WorkWell, as well as support from Work Coaches and Disability Employment Advisers in Jobcentres and Access to Work grants. Ministers and officials have regular conversations with regard to employment support for people whose ability to work is affected by a health condition.

The Government’s 10-Year Health Plan, published in July 2025, builds on existing work to better integrate health with employment support and incentivise greater cross-system collaboration. The plan outlines how the neighbourhood health service will join up support from across the work, health, and skills systems to help address the multiple complex challenges that often stop people finding and staying in work and deliver holistic care that leads to better employment outcomes for all.

Employers are also crucial in enhancing employment opportunities and supporting disabled people and people with health conditions, such as migraines, to thrive in the workforce. To encourage employers to create disability inclusive workplaces, the Government continues to oversee the Disability Confident Scheme. This provides resources such as the Disability Confident Manager’s Guide, which includes guidance on flexible working and workplace adjustments, and which is available at the following link:

https://www.gov.uk/government/publications/disability-confident-and-cipd-guide-for-line-managers-on-employing-people-with-a-disability-or-health-condition

The Government’s offer to employers also comprises tailored guidance on supporting disabled people and people with health conditions in the workplace through its Support with Employee Health and Disability service. This includes guidance on disclosures and having conversations about health and disabilities, plus guidance on legal obligations and making reasonable adjustments. Further information on the Support with Employee Health and Disability service is available at the following link:

https://www.support-with-employee-health-and-disability.dwp.gov.uk/support-with-employee-health-and-disability

Additionally, in November 2025, Sir Charlie Mayfield published the Keep Britain Working Review, setting out recommendations to reshape how the Government works with employers to improve work and health outcomes through creating healthier, more inclusive workplaces. The Government is now working with volunteer employers, providers, and regions through a Vanguard Phase to test and refine approaches to help disabled workers and workers with long-term health conditions, including people affected by migraine, receive the support they need to remain and thrive in employment. Alongside the Department of Health and Social Care, the Department for Work and Pensions, and the Department for Business and Trade, National Health Service organisations are already participating in the Keep Britain Working Vanguard Phase to design a healthy working lifecycle standard and the accompanying Workplace Health Provision.

1st Jul 2026
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage employers to provide reasonable workplace support for employees affected by migraine.

The Government is committed to working collaboratively to support disabled people and people with health conditions, including people affected by migraine. The Department of Health and Social Care and the Department for Work and Pensions’ Joint Work and Health Directorate was established to co-ordinate Government activity to help disabled people and people with health conditions get good work, get on in that work, and to return to work as quickly as possible if they leave it.

The Department of Health and Social Care and the Department for Work and Pensions have a range of specialist initiatives, including those joining up health and employment support around the individual through programmes such as Employment Advisors in NHS Talking Therapies and WorkWell, as well as support from Work Coaches and Disability Employment Advisers in Jobcentres and Access to Work grants. Ministers and officials have regular conversations with regard to employment support for people whose ability to work is affected by a health condition.

The Government’s 10-Year Health Plan, published in July 2025, builds on existing work to better integrate health with employment support and incentivise greater cross-system collaboration. The plan outlines how the neighbourhood health service will join up support from across the work, health, and skills systems to help address the multiple complex challenges that often stop people finding and staying in work and deliver holistic care that leads to better employment outcomes for all.

Employers are also crucial in enhancing employment opportunities and supporting disabled people and people with health conditions, such as migraines, to thrive in the workforce. To encourage employers to create disability inclusive workplaces, the Government continues to oversee the Disability Confident Scheme. This provides resources such as the Disability Confident Manager’s Guide, which includes guidance on flexible working and workplace adjustments, and which is available at the following link:

https://www.gov.uk/government/publications/disability-confident-and-cipd-guide-for-line-managers-on-employing-people-with-a-disability-or-health-condition

The Government’s offer to employers also comprises tailored guidance on supporting disabled people and people with health conditions in the workplace through its Support with Employee Health and Disability service. This includes guidance on disclosures and having conversations about health and disabilities, plus guidance on legal obligations and making reasonable adjustments. Further information on the Support with Employee Health and Disability service is available at the following link:

https://www.support-with-employee-health-and-disability.dwp.gov.uk/support-with-employee-health-and-disability

Additionally, in November 2025, Sir Charlie Mayfield published the Keep Britain Working Review, setting out recommendations to reshape how the Government works with employers to improve work and health outcomes through creating healthier, more inclusive workplaces. The Government is now working with volunteer employers, providers, and regions through a Vanguard Phase to test and refine approaches to help disabled workers and workers with long-term health conditions, including people affected by migraine, receive the support they need to remain and thrive in employment. Alongside the Department of Health and Social Care, the Department for Work and Pensions, and the Department for Business and Trade, National Health Service organisations are already participating in the Keep Britain Working Vanguard Phase to design a healthy working lifecycle standard and the accompanying Workplace Health Provision.

1st Jul 2026
To ask the Secretary of State for Health and Social Care, whether he plans to collect or publish data on the number of people whose work capability is affected by migraine or related headache disorders.

The Office for National Statistics collects information on health conditions through the Labour Force Survey (LFS), which is based on interviews with people resident in households in the United Kingdom. The LFS covers this in two relevant ways. It asks respondents about their general health, including any specific conditions and whether these are long-term conditions that limit their ability to work. It also asks about periods of absence from work on health grounds, including which health condition caused that absence.

The general health section of the survey contains a range of impairment categories, informed by the Government Statistical Service (GSS) Impairment harmonised standard. However, this list does not currently identify headache or migraine-related disorders as a separate category. Such conditions would most likely be categorised as “other health problems or disabilities”. Under the current survey design, it is therefore not possible to identify people whose long-term work-limiting illness is specifically related to headaches or migraines. The GSS Harmonisation team is currently reviewing the disability and impairment standards, including the review of disability data harmonised standards, which is available at the following link:

https://analysisfunction.civilservice.gov.uk/policy-store/review-of-disability-data-harmonised-standards-findings-from-phase-2-of-our-research/

Any recommendations from that review would be considered when assessing future updates to the impairment categories collected through the LFS.

Meanwhile, the section about periods of absence from work on health grounds includes an option for headaches and migraines. Analysis using this classification is published regularly as part of an article on Sickness absence in the UK labour market, which is available at the following link:

https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/datasets/sicknessabsenceinthelabourmarket

As the question is linked to specific periods of absence, it cannot be used to estimate the number of people who may be affected by migraine or headache related disorders. Instead, it looks at the number of days lost from work through different reasons for sickness absence, including headaches and migraines, along with the number of occurrences of sickness absence.

1st Jul 2026
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the impact of migraine on levels of employment, absenteeism and economic inactivity in sufferers.

No assessment has been made of the potential impact of migraine on employment and economic inactivity. This information isn’t available as the Labour Force Survey (LFS), the primary source for data on labour market participation and economic inactivity, only reports figures by long‑term health condition and does not include a category for migraines.

However, LFS data shows that working-age people with a long-term health condition are less likely to be in employment than those without a long-term health condition, at 64.1% compared with 81.6%, and are around twice as likely to be economically inactive, at 31.5% compared with 14.6%. The data is available at the following link:

https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/datasets/labourmarketstatusofdisabledpeoplea08

1st Jul 2026
To ask the Secretary of State for Health and Social Care, if he will ensure that the Government provides, by 16 July 2026, the information requested by the Patient Safety Commissioner on (a) action taken in response to the Hughes Report, (b) outstanding steps required before Ministers can decide on redress and (c) a timetable for the Government’s full response, including on the establishment of compensation schemes for those harmed by pelvic mesh and sodium valproate.

The Patient Safety Commissioner wrote to the Prime Minister on 16 June, requesting information regarding internal and cross-Government discussions in relation to the Hughes Report, actions that have been taken beyond the Department, and the future plans regarding the implementation of its recommendations and a timetable for a full response.

The Department will provide any information required to support a timely response.

30th Jun 2026
To ask the Secretary of State for Health and Social Care, what guidance his Department provides to NHS and local authority professionals on responsibility for commissioning specialist night-time safety equipment for children with complex developmental disabilities.

The Children and Families Act 2014 requires that education, health, and social care services must work together to meet the needs of children and young people with special educational needs and disabilities (SEND).

Integrated care boards (ICBs) are responsible for commissioning services to meet the health needs of their local population, and responsibility for providing equipment to disabled people typically falls to the National Health Service and local authorities (LAs).

We expect ICBs to follow guidance from the National Institute for Health and Care Excellence (NICE). In 2022, NICE published guidance on Disabled children and young people up to 25 with severe complex needs, which is available at the following link:

https://www.nice.org.uk/guidance/ng213/chapter/Recommendations-on-service-organisation-integration-and-commissioning

This guidance encourages education, health, and social care services to work together and provide more coordinated support to children and young people.

In May 2023, NHS England issued statutory guidance setting out the requirement for ICBs to have an executive lead for SEND, who will lead on supporting the chief executive and the board to ensure the ICB performs its functions effectively in the interests of children and young people with SEND.

LAs in England have a statutory duty under various legislations, including the Care Act 2014, and the Children and Families Act 2014, to make arrangements for the provision of disability aids and community equipment, and to meet the assessed eligible needs of individuals who are resident in their area. Types of support include equipment to enable people to live more independently, such as grab rails, walking aids, and wheelchairs for short-term use.

Some LAs deliver this themselves but a significant number have external contracts for integrated community equipment services. Responsibility for managing the market for these services, including commissioning and oversight of delivery, rests with LAs.

16th Jun 2026
To ask the Secretary of State for Health and Social Care, whether his Department plans to commission updated research into the long-term health effects of Poly Implant Prothèse breast implants on women.

The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently funding any specific research into long-term health effects of Poly Implant Prothèse breast (PIP) implants but welcomes funding applications for research into any aspect of women’s health. Applications are subject to peer review and judged in open competition, with awards being made based on the importance of the topic to patients and health and care services, value for money and scientific quality.

The Department does not hold information related to breast implant safety research funded by other sources.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what assessment the Department has made of the levels of (a) sexually transmitted infections acquired in the context of dopamine agonist-induced hypersexuality and (b) unplanned pregnancies among women treated with dopamine agonists who have documented impulse control disorder-related hypersexual behaviours; and whether patients are routinely asked about current dopamine agonist use in abortion and sexual health services.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the use of artificial intelligence and digital tools within the NHS and the Medicines and Healthcare products Regulatory Agency to (a) detect potential dopamine agonist-related impulse control disorders and augmentation from prescribing and clinical records and (b) support earlier warnings and monitoring for patients at higher risk.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what data national bodies hold on (a) the number and proportion of people prescribed dopamine agonists who self-report impulse control disorders and (b) the number and proportion whose impulse control disorders are first reported by a family member, carer or other third party.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the number and proportion of patients who develop impulse control disorders while taking dopamine agonists and subsequently (a) continue dopamine agonist treatment and (b) are able to stop or switch treatment.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what evidence the Department has assessed on the average time from initiating a dopamine agonist, or increasing its dose, to (a) the onset or first report of impulse control disorder symptoms and (b) formal recognition and recording of dopamine agonist-associated impulse control disorders; and how those intervals vary by indication, care setting and method of detection.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what information national pharmacovigilance systems and clinical datasets provide on the range and relative frequency of withdrawal symptoms associated with dopamine agonist discontinuation, including anxiety, depression, autonomic symptoms, pain and craving.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the average length of time patients remain on dopamine agonists or partial dopamine agonists for each licensed indication, (b) the proportion of patients who require dose escalation and (c) the typical timing and magnitude of such escalation.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what data the Department holds on the average age at (a) initiation of dopamine agonist therapy, (b) first report or diagnosis of an impulse control disorder while taking a dopamine agonist and (c) bringing a legal claim relating to dopamine agonist-associated impulse control disorders.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what assessment the Department has made of risk factors for dopamine agonist-induced impulse control disorders, including age, renal impairment, duration of exposure, cumulative dose, polypharmacy, pre-existing depression or anxiety, attention deficit hyperactivity disorder, autism, bipolar disorder and prior addictive or impulsive behaviours.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome treated with dopamine agonists who have co-existing neurodevelopmental or psychiatric diagnoses, including attention deficit hyperactivity disorder, autism or bipolar disorder; and how many had documented impulse control disorders or addictive behaviours before dopamine agonist initiation.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what data the Department holds on the proportion of patients with restless legs syndrome alone, compared with patients with restless legs syndrome and attention deficit hyperactivity disorder, autism or bipolar disorder, who develop new impulse control disorders or worsening pre-existing impulse control traits after dopamine agonist exposure; and whether similar data are available for Parkinson’s disease patients with those co-morbidities.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what information his Department holds on (a) the likelihood of patients who develop one dopamine agonist-associated impulse control disorder developing additional impulse control disorders and (b) the combinations of (i) hypersexuality, (ii) binge eating, (iii) compulsive shopping, (iv) compulsive gambling and (v) risky investments that are most commonly reported.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the effectiveness of how dopamine agonist-related impulse control disorders and augmentation are taught and assessed in undergraduate medical education; and what postgraduate or continuing professional development training is available on dopamine agonist-related impulse control disorders, augmentation and withdrawal syndromes.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, whether his Department holds audit or research data on differences between neurology or movement disorder specialists and general practitioners in (a) warning patients and families about dopamine agonist-related impulse control disorders and augmentation, (b) monitoring for behavioural side effects at follow-up and (c) documenting impulse control disorders in a retrievable format for audit and research.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what guidance is issued to clinicians on discussing in advance with patients, and where appropriate their families, how treatment should be managed if severe impulse control disorders develop while taking dopamine agonists, including the option of recording the patient’s wishes about dose reduction or discontinuation.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.

11th Jun 2026
To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices when dopamine agonists are started or doses increased, (c) the incidence of new-onset diabetes or serious obesity-related complications in that group and (d) how those findings affect prescribing or dose decisions.

The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.

Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.

The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.

The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.